William (Bill) Hunter MD to Join Adherium Board
16 Dec 2015
Melbourne, Australia, 16 December 2015: Adherium Limited (ASX: ADR), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, today confirmed that Canada-based pharmaceutical entrepreneur William (Bill) Hunter MD has agreed to join the Adherium Board as a non-executive director.
Dr Hunter is currently the President and CEO of renowned Cardiome Pharma Corp (NASDAQ: CRME) based in Vancouver, Canada. Cardiome is a specialty pharmaceutical company with three cardiology products approved in Europe and globally. Under Dr Hunter’s leadership, Cardiome has built its own direct sales force in Europe, acquired another company and product, assembled an international distribution network and in-licensed three additional products leading to an increase in Cardiome’s valuation beyond $200m.
Having made a career out of inventing and improving medical devices, Dr Hunter has 200 patents and patent applications to his name and has been involved in the discovery and development of several key devices and products used in over 10 million patients with total revenues exceeding $12 billion.
His latest venture, Canary Medical, utilises sensor technology to allow implanted medical devices to “self-report” on function, activity, wear, complications and patient outcomes, and in the analysis of the data generated by those devices.
While still in medical school, Dr Hunter co-founded Angiotech Pharmaceuticals. After becoming CEO and President of Angiotech he led the company through three rounds of private equity financing, IPO stage and listing on the Toronto Stock Exchange and NASDAQ, over $1b in equity and debt financings, a debt restructuring and eight separate corporate acquisitions. Worldwide annual revenues exceeded $250m.
“Bill has an impressive history commercialising medical devices. He is a major asset for the Adherium boardroom as we escalate international commercialisation of our products and services,” said Adherium Chairman Doug Wilson.
Dr Hunter is currently a director of Epirus Biopharmaceuticals Inc (NASDAQ: EPRS), Rex Bionics (AIM: RXB) as well as Cardiome. He has been awarded with the 2006 Principal Award from the Manning Foundation (one of Canada’s highest awards for innovation); BC Innovation Council’s Cecil Green Award for Science and Technology Entrepreneurship; Entrepreneur of the Year from the Canadian Venture Capital and Private Equity Association; and Canada’s 40 Under 40. He has a BSc from McGill University and a MSc and MD degree from the University of British Columbia.